
Biotech and Pharma M&A Activity Poised for Growth in 2026
The biotech sector is reaching a turning point as development-stage companies are maturing, with drugs gaining approvals and generating revenue, leading to increased profitability and attracting more generalist investor interest, supported by optimistic financial forecasts through 2030.

